Core Viewpoint - Chenguang Biotech has achieved a significant innovation by obtaining approval for sodium chlorogenic acid as a new feed additive, marking a pioneering breakthrough in China's feed industry [1] Group 1: Product Innovation - Sodium chlorogenic acid is extracted from stevia leaves and has been developed using a proprietary short-chain alcohol mixed solution extraction technology, enhancing the yield of the main product, steviol glycosides, while also creating a new product with antioxidant, anti-inflammatory, and antiviral properties [1] - This innovation fills a gap in the global market and improves resource utilization, opening new avenues for the comprehensive use of stevia [1] Group 2: Application in Livestock - In the livestock sector, sodium chlorogenic acid has demonstrated significant functional value, effectively enhancing the immune and antioxidant capabilities of weaned piglets and late-stage laying hens, optimizing gut microbiota, and improving nutrient absorption efficiency [1] - Experimental data indicates that its safety and efficacy meet industry-leading standards [1] Group 3: Market Position and Future Prospects - Chenguang Biotech specializes in the extraction, separation, purification, and application of plant active ingredients, with a diverse product range that includes natural pigments, spices, sweeteners, and health products, positioning it as a leader in the industry [2] - The successful development and application of sodium chlorogenic acid will further solidify Chenguang Biotech's leading position, enhance its brand influence, and increase market competitiveness [2] - The R&D team is accelerating the exploration of sodium chlorogenic acid's applications in food, health products, and pharmaceuticals, with potential in functional food development and chronic disease prevention [2]

内容概要：维生素是维持动物正常生理功能所必需的低分子有机化合物。与其它营养物质相比，动物对 维生素的需要量极微，但其生理作用却很大，维生素以辅酶和催化剂的形式广泛参与体内的代谢反应， 以维持动物的正常生产和繁殖活动。而维生素E作为一种脂溶性抗氧化剂，具有抗氧化作用，能够提高 肉质、促进生长与成活率，因此在动物饲料中应用广泛。数据显示，中国饲料添加剂中维生素产品产量 呈现波动上升趋势，其中2022年中国饲料级维生素E产量同比下降8.3%，这主要是因为终端养殖业陷入 亏损，对成本控制意愿强烈，从而减少了对维生素产品的需求。随后2023年行业产量逐渐恢复，但到了 2024年，中国饲料级维生素E产量达到6.3万吨，同比下降3.2%。 相关上市企业：新和成（002001）、浙江医药（600216）、能特科技（002102）、牧原股份 （002714）、禾丰股份（603609）、新希望（000876）、通威股份（600438）、温氏股份（300498）、 海大集团（002311）、大北农（002385）等。 相关企业：帝斯曼（中国）有限公司、郑州龙生化工产品有限公司、南京诺齐生物科技有限公司、新发 药业有限公司等。 关键 ...

Core Viewpoint - Blue Star Adisseo Co., Ltd. is seeking to raise funds through a specific stock issuance, with a total investment of 6.857 billion yuan for four projects and working capital, aiming for an internal rate of return between 13.57% and 25% [2][3]. Fundraising and Investment Projects - The total investment for the fundraising projects is 6.857 billion yuan, with a maximum of 3 billion yuan to be raised, allocated to four projects and 900 million yuan for working capital [2]. - The construction period for the four projects ranges from 15 to 26 months, with expected benefits from cost reductions and additional income from biogas [2]. Project Details - The first project is a solid methionine production project with an investment of approximately 493.23 million yuan, accounting for 100% of the total investment for this project [3][4]. - The second project involves a special feed additive with a total investment of 304.97 million yuan, with 60 million yuan sourced from the fundraising [11]. - The third project focuses on acrylic wastewater treatment and water reuse, with a total investment of 324.97 million yuan and 100 million yuan from the fundraising [15][19]. Cost Estimation and Reasonableness - The cost estimation for the solid methionine project is based on market prices and relevant cost estimation methods, ensuring its reasonableness [4][5]. - The unit construction cost for the solid methionine project is 3,593.25 yuan per square meter, which is within the range of similar projects in the region [7][12]. - The equipment costs for the projects are estimated based on supplier quotes and historical prices, ensuring that the pricing is reasonable [13][14]. Financial Justification - The financing scale is justified by the company's operational needs, cash flow, and projected funding gaps, with a future funding shortfall of approximately 5.566 billion yuan over the next three years [19].

浙江圣达生物药业股份有限公司 ZHEJIANG SHENGDA BIO-PHARM CO., LTD. （浙江省天台县赤城街道人民东路789号） 向特定对象发行股票 募集说明书 （注册稿） 保荐人（主承销商） （北京市朝阳区安立路66号4号楼） 二〇二五年五月 圣达生物向特定对象发行股票 募集说明书 声 明 中国证监会、上海证券交易所对本次发行所作的任何决定或意见，均不表明 其对申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对 发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何 与之相反的声明均属虚假不实陈述。 根据《证券法》规定，证券依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 证券依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 投资者若对本募集说明书存在任何疑问，应咨询自己的股票经纪人、律师、 会计师或其他专业顾问。 圣达生物向特定对象发行股票 募集说明书 重大事项提示 公司特别提请投资者注意，在作出投资决策之前，务必仔细阅读本募集说明 书正文内容，并特别关注以下重要事项。 一、本 ...